In the preceding three months, 27 analysts have released ratings for Gilead Sciences GILD, presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 13 | 12 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 2 | 0 | 0 |
| 2M Ago | 0 | 8 | 7 | 0 | 0 |
| 3M Ago | 0 | 2 | 3 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $96.0, along with a high estimate of $125.00 and a low estimate of $70.00. Observing a 14.82% increase, the current average has risen from the previous average price target of $83.61.
Interpreting Analyst Ratings: A Closer Look
A clear picture of Gilead Sciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tim Anderson | B of A Securities | Announces | Buy | $109.00 | - |
| Hartaj Singh | Oppenheimer | Raises | Outperform | $115.00 | $105.00 |
| Colin Bristow | UBS | Raises | Neutral | $96.00 | $70.00 |
| Salim Syed | Mizuho | Raises | Outperform | $100.00 | $90.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $84.00 | $81.00 |
| Alexandria Hammond | Wolfe Research | Announces | Outperform | $110.00 | - |
| Geoff Meacham | Citigroup | Announces | Buy | $125.00 | - |
| Asthika Goonewardene | Truist Securities | Raises | Hold | $97.00 | $83.00 |
| Hartaj Singh | Oppenheimer | Raises | Outperform | $105.00 | $95.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $102.00 | $94.00 |
| Brian Skorney | Baird | Raises | Neutral | $95.00 | $80.00 |
| Chris Schott | JP Morgan | Raises | Overweight | $105.00 | $100.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $81.00 | $75.00 |
| Salveen Richter | Goldman Sachs | Raises | Neutral | $84.00 | $74.00 |
| Olivia Brayer | Cantor Fitzgerald | Raises | Neutral | $80.00 | $70.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $105.00 | $100.00 |
| Carter Gould | Barclays | Raises | Equal-Weight | $95.00 | $84.00 |
| Joseph Catanzaro | Piper Sandler | Raises | Overweight | $105.00 | $95.00 |
| Brian Abrahams | RBC Capital | Maintains | Sector Perform | $75.00 | $75.00 |
| Andrew Berens | Leerink Partners | Raises | Outperform | $96.00 | $74.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $94.00 | $85.00 |
| Aaron Gal | Bernstein | Announces | Outperform | $105.00 | - |
| Chris Schott | JP Morgan | Raises | Overweight | $100.00 | $95.00 |
| Carter Gould | Barclays | Raises | Equal-Weight | $84.00 | $76.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $100.00 | $78.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $75.00 | $74.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $70.00 | $70.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Gilead Sciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Gilead Sciences's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Gilead Sciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Gilead Sciences analyst ratings.
Get to Know Gilead Sciences Better
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
A Deep Dive into Gilead Sciences's Financials
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Gilead Sciences showcased positive performance, achieving a revenue growth rate of 7.02% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Gilead Sciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Gilead Sciences's ROE excels beyond industry benchmarks, reaching 6.82%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Gilead Sciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.32%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.26, Gilead Sciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
